Clinical Trials for DTx
Digital therapeutics are recognized on par with medications and other clinically-validated therapies by demonstrating their power to improve patient outcomes through peer-reviewed research through rigorous clinical trials. Unlike traditional medications, DTx products can be iterated and improved. Peer-reviewed research from digital medicines enables companies to continue iterating products that best serve our patients.
Further, Digital therapeutics have the power to reveal insights through research that analog medicines can’t access. Prior to therapeutics, studies like this were largely reliant on hospitalization or mortality data to assess how patients respond to environmental factors. Exacerbations that didn’t involve hospitalization or fatalities were overlooked because the data didn’t necessarily exist. Digital therapeutics research represents a huge area of opportunity to better understand how patients use medication and experience chronic disease.
DTA already sees pharmaceutical companies, payers and healthcare organizations make investments in digital medicines, and we expect to see that investment increase as consumers grow to expect a digital component to their medication regimen.